| Literature DB >> 29578252 |
M Augustussen1, M L Pedersen2, L Hounsgaard1,2,3, H Timm4, P Sjøgren5.
Abstract
A prospective national cohort study assessed the development of health-related quality of life (HRQoL) and symptoms in adult patients undergoing treatment and care for advanced cancer in Greenland. HRQol was examined by EORTC QLQ-C30 version 3.0 questionnaire monthly for 4 months. Changes over time and between-group comparisons were examined. Of 58 patients included in the study, 47% completed the questionnaire four times. Functioning was generally high, and improved social functioning was observed after 1 and 2 months. The highest symptom score was for fatigue followed by pain and nausea/vomiting. A high score for financial problems remained unchanged during the entire period. Patients with higher income had reduced pain intensity (p = .03) and diarrhoea (p = .05) than patients with income below the poverty line. After 1 month, reduction in pain intensity was observed for Nuuk citizens compared with non-Nuuk citizens (p = .05). After 2 months, non-Nuuk citizens reported improved social functioning compared with Nuuk citizens (p = .05). After 3 months, Global Health in Nuuk citizens was improved compared with non-Nuuk citizens (p = .05). An important clinical finding was that patients' needs for support are related to social status, and geographical factors should be taken into account when planning palliative care.Entities:
Keywords: health-related quality of life; palliative care; prospective study; remote areas; symptom management
Mesh:
Year: 2018 PMID: 29578252 PMCID: PMC6001430 DOI: 10.1111/ecc.12843
Source DB: PubMed Journal: Eur J Cancer Care (Engl) ISSN: 0961-5423 Impact factor: 2.520
Figure 1Flow diagram illustrating participating patients and dropout
Basic characteristics of participants with advanced cancer
| Characteristics | All | Male | Female |
|---|---|---|---|
| Mean age ( | 59 | 62 (9) | 56 (8) |
| Single living, | 23 (39) | 13 (35) | 10 (47) |
| Lung cancer, | 26 (45) | 20 (54) | 6 (29) |
| Low income < 14.980 USD | 30 (51) | 17 (46) | 13 (62) |
| Nuuk resident, | 14 (24) | 7 (19) | 7 (33) |
| No education/elementary school, | 20 (34) | 10 (27) | 10 (47) |
Overview of mean scores from baseline to the third month
| Baseline mean ( | After 1 month ( | After 2 months ( | After 3 months ( | |
|---|---|---|---|---|
| Functional scales | ||||
| Physical functioning | 69 (22) | 64 (24) | 63 (24) | 62 (23) |
| Role functioning | 63 (31) | 53 (31) | 59 (32) | 50 (32) |
| Emotional functioning | 77 (21) | 76 (23) | 79 (24) | 81 (17) |
| Cognitive functioning | 76 (24) | 81 (22) | 75 (24) | 72 (28) |
| Social functioning | 55 (35) | 66 (31) | 68 (29) | 62 (37) |
| Global health status/QoL | 66 (23) | 59 (23) | 70 (22) | 61 (24) |
| Symptom scales | ||||
| Fatigue | 39 (27) | 41 (27) | 37 (32) | 44 (29) |
| Nausea/vomiting | 11 (15) | 17 (27) | 14 (18) | 18 (25) |
| Pain | 31 (27) | 28 (32) | 36 (38) | 37 (34) |
| Single items | ||||
| Dyspnoea | 25 (33) | 32 (36) | 29 (30) | 39 (39) |
| Insomnia | 28 (31) | 30 (34) | 27 (36) | 28 (34) |
| Appetite loss | 24 (31) | 24 (29) | 27 (38) | 38 (40) |
| Constipation | 21 (32) | 25 (32) | 21 (36) | 32 (36) |
| Diarrhoea | 19 (28) | 15 (25) | 15 (25) | 13 (23) |
| Financial problems | 33 (41) | 37 (41) | 35 (40) | 33 (45) |
Changes in mean scores for all patients from baseline to T1, T2 and T3
| Change T1–T0 |
| Change T2–T0 |
| Change T3–T0 |
| |
|---|---|---|---|---|---|---|
| Physical functioning | −4 | .4404 | −5 | .3444 | −4 | .3014 |
| Role functioning | −7 | .0866 | 2 | .7968 | −2 | .8944 |
| Emotional functioning | 0 | .7287 | 3 | .8032 | 5 | .1863 |
| Cognitive functioning | 2 | .5239 | −2 | .8133 | −5 | .5523 |
| Social functioning | 10 | .009 | 13 | .0012 | 9 | .1001 |
| Global health status/QoL | −8 | .009 | 3 | .3734 | −6 | .1989 |
| Fatigue | 4 | .1065 | 1 | .8754 | 8 | .1806 |
| Nausea/vomiting | 6 | .1048 | 3 | .3929 | 8 | .1191 |
| Pain | −4 | .3954 | 5 | .1910 | 3 | .7008 |
| Dyspnoea | 5 | .3364 | 0 | .9496 | 5 | .6773 |
| Insomnia | −1 | .9506 | −2 | .7917 | −1 | 1 |
| Appetite loss | 1 | .8539 | 5 | .3879 | 12 | .0979 |
| Constipation | 4 | .3232 | 1 | .7693 | 10 | .2676 |
| Diarrhoea | 3 | .4366 | 2 | .6914 | 0 | 1 |
| Financial problems | 3 | .7328 | 0 | .9608 | −6 | .5664 |
Statistically significant p‐value marked with*.